MANNKIND CORP Operating Lease, Payments
MANNKIND CORP (MNKD) reported Operating Lease, Payments of $806.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-05
- MANNKIND CORP operating lease, payments for the quarter ending 2026-06-30 was $806.00K, a 12.30% decline year-over-year.
- MANNKIND CORP operating lease, payments for the quarter ending 2026-03-31 was $939.00K, a 3.40% decline year-over-year.
- MANNKIND CORP operating lease, payments for the quarter ending 2025-12-31 was $973.00K, a 9.94% increase year-over-year.
- MANNKIND CORP operating lease, payments for the quarter ending 2025-09-30 was $873.00K, a 1.51% increase year-over-year.
- MANNKIND CORP operating lease, payments for fiscal 2025 was $3.74M, a 63.05% increase from fiscal 2024.
- MANNKIND CORP operating lease, payments for fiscal 2024 was $2.29M, a 114.61% increase from fiscal 2023.
- MANNKIND CORP operating lease, payments for fiscal 2023 was $1.07M, a 41.42% decline from fiscal 2022.
- MANNKIND CORP operating lease, payments for fiscal 2022 was $1.82M, a 0.00% change from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 9 month as first filed | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $806.00K 10-Q · filed 2026-08-05 | $1.75M 10-Q · filed 2026-08-05 | $2.72M derived: sum of 3 quarters · filed 2026-08-05 | $3.59M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $939.00K 10-Q · filed 2026-05-06 | $1.91M derived: sum of 2 quarters · filed 2026-05-06 | $2.79M derived: sum of 3 quarters · filed 2026-05-06 | $3.70M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $973.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.85M derived: sum of 2 quarters · filed 2026-02-26 | $2.77M derived: sum of 3 quarters · filed 2026-08-05 | $3.74M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $873.00K 10-Q · filed 2025-11-05 | $1.79M derived: sum of 2 quarters · filed 2026-08-05 | $2.76M 10-Q · filed 2025-11-05 | $3.65M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $919.00K 10-Q · filed 2026-08-05 | $1.89M 10-Q · filed 2026-08-05 | $2.78M derived: sum of 3 quarters · filed 2026-08-05 | $3.64M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $972.00K 10-Q · filed 2026-05-06 | $1.86M derived: sum of 2 quarters · filed 2026-05-06 | $2.72M derived: sum of 3 quarters · filed 2026-05-06 | $3.03M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $885.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.75M derived: sum of 2 quarters · filed 2026-02-26 | $2.06M derived: sum of 3 quarters · filed 2026-02-26 | $2.29M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $860.00K 10-Q · filed 2025-11-05 | $1.17M derived: sum of 2 quarters · filed 2025-11-05 | $1.41M 10-Q · filed 2025-11-05 | $1.65M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $314.00K 10-Q · filed 2025-08-06 | $546.00K 10-Q · filed 2025-08-06 | $789.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.06M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $232.00K 10-Q · filed 2025-05-08 | $475.00K derived: sum of 2 quarters · filed 2026-02-26 | $743.00K derived: sum of 3 quarters · filed 2026-02-26 | $977.00K derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $511.00K derived: sum of 2 quarters · filed 2026-02-26 | $745.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.07M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $268.00K 10-Q · filed 2024-11-07 | $502.00K derived: sum of 2 quarters · filed 2024-11-07 | $825.00K 10-Q · filed 2024-11-07 | $1.32M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $234.00K 10-Q · filed 2024-08-07 | $557.00K 10-Q · filed 2024-08-07 | $1.05M derived: sum of 3 quarters · filed 2024-08-07 | $1.49M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $323.00K 10-Q · filed 2024-05-08 | $818.00K derived: sum of 2 quarters · filed 2024-05-08 | $1.26M derived: sum of 3 quarters · filed 2024-05-08 | $1.71M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $936.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.38M derived: sum of 3 quarters · filed 2024-02-27 | $1.82M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | $441.00K 10-Q · filed 2023-11-07 | $887.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.33M 10-Q · filed 2023-11-07 | $1.78M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-06-30 | $446.00K 10-Q · filed 2023-08-07 | $887.00K 10-Q · filed 2023-08-07 | $1.34M derived: sum of 3 quarters · filed 2025-02-26 | $1.79M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-03-31 | $442.00K 10-Q · filed 2023-05-09 | $898.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.35M derived: sum of 3 quarters · filed 2025-02-26 | $1.80M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2021-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $907.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.36M derived: sum of 3 quarters · filed 2025-02-26 | $1.82M 10-K · filed 2025-02-26 | $1.87M 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $451.00K 10-Q · filed 2022-11-08 | $905.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.37M 10-Q · filed 2022-11-08 | $1.81M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $454.00K 10-Q · filed 2022-08-09 | $916.00K 10-Q · filed 2022-08-09 | $1.36M derived: sum of 3 quarters · filed 2023-02-23 | $1.83M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $461.00K 10-Q · filed 2022-05-05 | $461.30K 10-Q · filed 2021-05-12 | $909.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.38M derived: sum of 3 quarters · filed 2023-02-23 | $1.81M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $914.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.34M derived: sum of 3 quarters · filed 2023-02-23 | $1.80M 10-K · filed 2023-02-23 | $1.80M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $466.00K 10-Q · filed 2021-11-09 | $500.00K 10-Q · filed 2020-11-04 | $897.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.35M 10-Q · filed 2021-11-09 | $1.30M 10-Q · filed 2020-11-04 | $1.85M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $431.00K 10-Q · filed 2021-08-11 | $400.00K 10-Q · filed 2020-08-05 | $883.00K 10-Q · filed 2021-08-11 | $900.00K 10-Q · filed 2020-08-05 | $1.38M derived: sum of 3 quarters · filed 2021-08-11 | $1.88M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $452.00K 10-Q · filed 2021-05-12 | $400.00K 10-Q · filed 2020-05-06 | $952.00K derived: sum of 2 quarters · filed 2021-05-12 | $1.45M derived: sum of 3 quarters · filed 2021-05-12 | $1.65M derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.00M derived: sum of 2 quarters · filed 2021-02-25 | $1.20M derived: sum of 3 quarters · filed 2021-02-25 | $1.80M 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | $500.00K 10-Q · filed 2020-11-04 | $700.00K derived: sum of 2 quarters · filed 2020-11-04 | $1.30M 10-Q · filed 2020-11-04 | |||||
| 2019-06-30 | $200.00K 10-Q · filed 2020-08-05 | $700.00K 10-Q · filed 2020-08-05 | ||||||
| 2019-03-31 | $500.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |